Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
CERE was delisted on the 31st of July, 2024.
210 hedge funds and large institutions have $6.67B invested in Cerevel Therapeutics Holdings, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 45 funds opening new positions, 82 increasing their positions, 49 reducing their positions, and 29 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 49
55% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 29
27% more call options, than puts
Call options by funds: $60M | Put options by funds: $47.1M
8% more funds holding
Funds holding: 195 → 210 (+15)
0% more capital invested
Capital invested by funds: $6.64B → $6.67B (+$31.3M)
9% less funds holding in top 10
Funds holding in top 10: 11 → 10 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Soros Fund Management
New York
|
+$81.5M |
| 2 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$63.2M |
| 3 |
Citigroup
New York
|
+$58.1M |
| 4 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$47M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$38.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$332M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$89.3M |
| 3 |
Morgan Stanley
New York
|
-$41.9M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$36.3M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
-$33.3M |
CERE Hedge Fund Activity: Q1 2024 in Review
210 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) for Q1 2024, worth a combined $6.67B — up 0.47% from $6.64B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new CERE positions and 29 closed out — a net gain of 16 holders — while 82 added to existing stakes and 49 trimmed.
The largest buyer was Soros Fund Management, opening a new position worth an estimated $81.5M. The largest seller was Fidelity Investments, cutting an estimated $332M.
- 210 institutional investors held Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) as of Q1 2024, up from 195 in Q4 2023.
- Funds reported $6.67B of Cerevel Therapeutics Holdings, Inc. Common Stock stock for Q1 2024, up 0.47% quarter-over-quarter.
- 45 funds opened new Cerevel Therapeutics Holdings, Inc. Common Stock positions in Q1 2024 and 29 closed out, a net change of +16 holders.
- The largest Cerevel Therapeutics Holdings, Inc. Common Stock buyer in Q1 2024 was Soros Fund Management, an estimated $81.5M added.
- The largest Cerevel Therapeutics Holdings, Inc. Common Stock seller in Q1 2024 was Fidelity Investments, an estimated $332M sold.
Based on aggregated 13F filings for Q1 2024.